1. Volume 56, Issue 2, Pages 650-658 (August 1999)
Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy 
Hiroki Yokoyama, Ken Sato, Maki Okudaira, Chihiro Morita, Chieko Takahashi, Daisuke Suzuki, Hideto Sakai, Yasuhiko Iwamoto 
Kidney International 
Volume 56, Issue 2, Pages (August 1999)
DOI: /j x
Copyright © 1999 International Society of Nephrology Terms and Conditions

2. Figure 1
Fluid phase inhibition of 10E4 biding to chemically modified heparan sulfate (HS). Symbols are: (•) HS, heparan sulfate containing N-sulfate, 6-O-sulfate, and 2-O-sulfate; (▪) CDSNAc-HS, completely desulfated, N-acetylated HS; (▴) CDSNS-HS, completely desulfated, N-sulfated HS; (X) NDSNAc-HS, N-desulfated, N-acetylated HS.
Kidney International  , DOI: ( /j x)
Copyright © 1999 International Society of Nephrology Terms and Conditions

3. Figure 2
Immunohistochemical staining with heparan sulfate (HS) 10E4 antibody. (A) A glomerulus from a nondiabetic subject that demonstrates a linear staining pattern in the glomerular basement membrane and mesangial area (×400, score = 4). (B) A glomerulus from a patient with diabetic nephropathy with moderate mesangial expansion that shows diminished staining (×400, score = 2). (C) A glomerulus from a patient with diabetic nephropathy with severe mesangial expansion that shows that the staining intensity was totally diminished (×400, score = 0).
Kidney International  , DOI: ( /j x)
Copyright © 1999 International Society of Nephrology Terms and Conditions

4. Figure 3
Score of intensity of human glomeruli stained immunohistochemically with heparan sulfate (HS) 10E4 antibody in nondiabetic subjects (subjects 1 through 3), diabetic subjects with normoalbuminuria (subjects 4 through 6) and overt proteinuria (subjects 7 through 11). Data are mean ±sem.
Kidney International  , DOI: ( /j x)
Copyright © 1999 International Society of Nephrology Terms and Conditions